Filter Results:
(5,085)
Show Results For
- All HBS Web
(5,085)
- People (18)
- News (1,641)
- Research (2,747)
- Events (5)
- Multimedia (111)
- Faculty Publications (1,760)
Show Results For
- All HBS Web
(5,085)
- People (18)
- News (1,641)
- Research (2,747)
- Events (5)
- Multimedia (111)
- Faculty Publications (1,760)
- 17 Jan 2024
- HBS Case
Psychological Pricing Tactics to Fight the Inflation Blues
Many consumers recovering from the worst inflation in 40 years continue to closely watch their spending—they want to know that every expense is worth it. Now companies must confront a major challenge: gauging how much, if any, of their... View Details
- 07 Sep 2011
- First Look
First Look: Sept. 7
Crisis in Health Care Authors:Robert S. Kaplan and Michael E. Porter Publication:Harvard Business Review 89, no. 9 (September 2011) Abstract Existing View Details
Keywords: Sean Silverthorne
- Spring 2021
- Article
Corporate Resilience and Response During COVID-19
By: Alex Cheema-Fox, Bridget LaPerla, George Serafeim and Hui (Stacie) Wang
The coronavirus pandemic caused a sharp market decline while raising heterogeneous responses across companies related to their employees, supply chain, and repurposing of operations to provide needed products and services. We study whether during the 2020 COVID-19... View Details
Keywords: ESG; COVID-19; Coronavirus; Crisis Response Plans; Crisis; ESG (Environmental, Social, Governance) Performance; ESG Ratings; Leadership & Corporate Accountability; Big Data; Machine Learning; Investor Behavior; Institutional Investors; Corporate Performance; Health Pandemics; Crisis Management; Corporate Social Responsibility and Impact; Human Capital; Supply Chain; Operations; Leadership; Corporate Accountability; Institutional Investing; Performance
Cheema-Fox, Alex, Bridget LaPerla, George Serafeim, and Hui (Stacie) Wang. "Corporate Resilience and Response During COVID-19." Journal of Applied Corporate Finance 33, no. 2 (Spring 2021): 24–40.
- February 2002 (Revised August 2002)
- Case
Inhale Therapeutics: Executing and Growing the Business Model
Inhale is about to bring a novel technology to market that uses inhalation to administer drugs that formerly required injection. Inhale must now decide which way to evolve its business model. This will determine the future direction of growth for the company. View Details
Keywords: Business Model; Technological Innovation; Health Care and Treatment; Growth and Development Strategy; Medical Devices and Supplies Industry
Chesbrough, Henry W., and Gillian Morris. "Inhale Therapeutics: Executing and Growing the Business Model." Harvard Business School Case 602-132, February 2002. (Revised August 2002.)
- 22 Apr 2020
- News
The Curious Case of the Coronavirus Commercial
- 20 Feb 2007
- First Look
First Look: February 20, 2007
Co.: Breaking New Grounds Harvard Business School Case 807-004 Examines the strategies of a Boston-based start-up to market Rwandan coffee. Describes the history of the coffee industry, the era of cartelization and the International... View Details
Keywords: Martha Lagace
- 05 Mar 2013
- First Look
First Look: March 5
abstract available. Purchase this case:http://hbr.org/search/213051-PDF-ENG Kirkpatrick Corporation Hawkins, David F. Harvard Business School Case 113-070 No abstract available. Purchase this case:http://hbr.org/search/113070-PDF-ENG Social Media View Details
Keywords: Sean Silverthorne
- 16 Jul 2007
- Research & Ideas
Understanding the ‘Want’ vs. ’Should’ Decision
desires (e.g., spending instead of saving money, eating junk food instead of health food). The should-self, on the other hand, prefers to behave in a way that will maximize long-run benefits. If left to its... View Details
- 25 Jun 2020
- Blog Post
Harvard Business School Class of 2021 Student Profiles
Health Care Club, Co-President, PRIDE Club, Soccer Club, Tech Club, Management Consulting Club Christina Byrd “While working on cross-functional and strategic initiatives at Uber,” says Christina, “I... View Details
- 25 Mar 2021
- Blog Post
Meet the Student Academic Services Support Team at HBS!
resources, issues of safety, respect, and inclusion, as well as health management and disability services. Four staff members have mental health licensure in the state of... View Details
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Health Industry; Health Industry; Health Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- October 1990 (Revised April 1991)
- Case
RU 486 (A)
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details
Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Health Industry; Health Industry; France; Germany; United States
Badaracco, Joseph L., Jr. "RU 486 (A)." Harvard Business School Case 391-050, October 1990. (Revised April 1991.)
- Web
Great American Business Leaders of the 20th Century - Leadership
expand dramatically Transistors used in portable radios and calculators Influence: Medium-High 60 1960 19 Man walks on the moon Color TV market grows Microchips expand possibilities View Details
- Web
Program Requirements - Doctoral
developed for understanding—health care organizations. Coursework Health Policy Core Seminar (Health Policy 2000) Microeconomic Theory (Econ 2020a/b; HKS API 101Z/102Z; or HKS API 109/110; Econ 1460 may be... View Details
- 06 Mar 2007
- First Look
First Look: March 6, 2007
understand why some of the other top firms in the business, such as KKR and Apollo, have been tapping the public equity markets for their own funds, and whether they should do the same. They are also... View Details
Keywords: Martha Lagace
- February 2019 (Revised July 2025)
- Case
Theranos: Who Has Blood on Their Hands? (A)
By: Nien-hê Hsieh, Christina R. Wing, Emilie Fournier and Anna Resman
This case covers the rise and fall of Theranos, the company founded by Elizabeth Holmes in 2004 to revolutionize the blood testing industry by creating a device that could provide from a small finger prick the same results and accuracy as intravenous blood draws. As... View Details
Keywords: Health Testing and Trials; Corporate Accountability; Organizational Culture; Misleading and Fraudulent Advertising; Crime and Corruption; Ethics; Entrepreneurship; Lawsuits and Litigation
Hsieh, Nien-hê, Christina R. Wing, Emilie Fournier, and Anna Resman. "Theranos: Who Has Blood on Their Hands? (A)." Harvard Business School Case 619-039, February 2019. (Revised July 2025.)
- January 2021 (Revised June 2021)
- Case
Hester Pharmaceuticals (A): A Pricing Dilemma
By: Dante Roscini and John Masko
In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details
Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (A): A Pricing Dilemma." Harvard Business School Case 721-001, January 2021. (Revised June 2021.)
- February 2022
- Case
Paul Polman
By: Elizabeth A. Keenan, Youngme Moon and Susie Ma
Over his 40-year career, Paul Polman had led some of the world’s largest consumer goods companies, making his biggest mark as CEO of Unilever—a multi-national corporation that produced everything from soap to soup. Polman was also well-regarded as a leader in corporate... View Details
Keywords: Marketing; Brands and Branding; Marketing Communications; Marketing Strategy; Leadership; Corporate Accountability; Personal Development and Career; Corporate Social Responsibility and Impact; Ethics; Values and Beliefs; Social Issues; Philanthropy and Charitable Giving
Keenan, Elizabeth A., Youngme Moon, and Susie Ma. "Paul Polman." Harvard Business School Case 322-098, February 2022.
- 01 Mar 2024
- News
Vital Signs
Image by Edmon De Haro Illustration by Edmon De Haro The signs of strain were there long before the pandemic: Health care workers had been managing under tremendous pressures while working long hours View Details
- April 2024
- Case
Dr. Tom Mihaljevic and Cleveland Clinic
By: Linda A. Hill and Lydia Begag
In December 2022, Dr. Tomislav (“Tom”) Mihaljevic, CEO and President of Cleveland Clinic, was reflecting on the last few years at the hospital, marked both by unprecedented challenges and remarkable achievements. Cleveland Clinic had recently been ranked the world’s... View Details
Keywords: Recruitment; Retention; Analytics and Data Science; Digital Transformation; Digital Platforms; Innovation and Management; Innovation Leadership; Human Capital; Leadership Development; Leadership Style; Leading Change; Organizational Culture; Organizational Structure; Organizational Change and Adaptation; Mission and Purpose; Outcome or Result; Performance Evaluation; Health Pandemics; Goals and Objectives; Health Industry; Cleveland; London; Abu Dhabi; Florida; Ohio
Hill, Linda A., and Lydia Begag. "Dr. Tom Mihaljevic and Cleveland Clinic." Harvard Business School Case 424-031, April 2024.